After SQZ Biotechnologies presented clinical data from the enhanced Antigen Presenting Cell, or eAPC, and APC clinical trials at the ESMO-IO Congress, H.C. Wainwright analyst Emily Bodnar said that its "too early" to make any conclusions from initial eAPC data and that the APC combination data "do not look superior to monotherapy data." The analyst, who contends that the initial eAPC and APC combo data "raise more questions," keeps a Neutral rating on SQZ Biotechnologies shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SQZ:
- SQZ Biotechnologies receives FDA Fast Track Designation for eAPC candidate
- SQZ Biotechnologies downgraded to Neutral from Buy at H.C. Wainwright
- SQZ Biotechnologies price target lowered to $4 from $16 at Chardan
- SQZ Biotechnologies double-downgraded to Underperform at BofA
- SQZ Biotechnologies announces strategic prioritization, resignation of CEO/CFO